Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR7390 Combined with Camrelizumab and Fuzuloparib in Advanced Solid Tumors
NCT03182673Phase 1Terminated
- Sponsor
- Hengrui
- Start
- Jul 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SHR7390 in solid tumor (advanced stage) (2 arms), sponsored by Hengrui. Primary endpoints: Maximum Tolerated Dose up to 24 months and Dose-Limiting Toxicity up to 24 months. Started Jul 2017; status: terminated.
02
Drugs
SHR7390
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03182673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03182673.